Ibrutinib and Kratom: Interaction Details
- Ibrutinib
- Imbruvica
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Ibrutinib and Kratom interaction:
Kratom
We don't have a drug information page for Kratom yet. Have a question about Kratom? Ask a pharmacist, free →
What Happens When You Take Ibrutinib With Kratom
What can happen when they are taken together (rated Moderate)
Increased exposure
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When kratom, which inhibits CYP3A, is taken together with a CYP3A substrate, exposure to that substrate may rise, particularly with larger kratom doses or long-term use.1 Careful monitoring is recommended.2
The Ibrutinib and Kratom Interaction, Explained
Kratom is an herbal product that can slow down , a liver enzyme your body uses to break down ibrutinib (Imbruvica). When that enzyme is slowed, more ibrutinib can stay in your body. That may raise the chance of side effects such as bleeding or bruising, irregular heartbeat, infections, or diarrhea. This is more likely with larger amounts of kratom or with regular, long-term use.
Please don't stop or change anything on your own. Tell your pharmacist and your cancer care team if you use kratom. They can adjust your ibrutinib dose to fit you and may monitor you more closely so this can be handled safely.
Mechanism: Kratom (mitragynine and related alkaloids) inhibits . Ibrutinib is a CYP3A with extensive , so reduced is expected to increase ibrutinib exposure (/). Ibrutinib is not a , so higher exposure means enhanced effect and toxicity.
- Direction: increased ibrutinib exposure, greater with higher kratom doses or chronic use.
- Onset: unspecified. Evidence: probable. Severity: moderate.
- Monitor: bleeding, atrial fibrillation or , hypertension, infection, diarrhea, cytopenias.
- Management: ask about kratom use, monitor closely, and individualize ibrutinib dosing per labeling for CYP3A . Counsel on avoiding kratom where feasible.
See the 2 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Ibrutinib and Kratom Interact
The likely mechanism
of -mediated by kratom
How to Manage the Ibrutinib and Kratom Interaction
Your care team can manage this by tailoring your treatment and watching you more closely. The documented advice is close monitoring.
- Keep taking ibrutinib as prescribed unless your prescriber tells you otherwise.
- Tell your pharmacist and prescriber how much kratom you use and how often.
- Your ibrutinib dose may need to be adjusted and individualized by your care team.
- Report unusual bleeding or bruising, a racing or irregular heartbeat, signs of infection, or severe diarrhea.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Ibrutinib or Kratom need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Clinical assessment of the drug interaction potential of the psychotropic natural product kratom
An open-label crossover study in healthy adults (N=12) evaluated a single, low dose of kratom tea (2 g) taken together with oral midazolam ( probe ; 2.5 mg) and oral dextromethorphan ( probe substrate; 30 mg). Kratom produced modest increases in the geometric mean ratio for midazolam (1.39; 90% CI, 1.23 to 1.57) and (1.5; 90% CI, 1.32 to 1.7), while dextromethorphan AUC and Cmax were unaffected.
Midazolam half life did not change significantly with concurrent kratom use, which suggests of , mainly by CYP3A in the intestine. The participants (median age, 30 years) had previously been exposed to kratom and agreed to refrain from medications and from botanical or other natural products (including kratom) throughout the study.1
Ibrutinib and Kratom: Common Questions
How serious is the Ibrutinib and Kratom interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How is the Ibrutinib and Kratom interaction managed?
Your care team can manage this by tailoring your treatment and watching you more closely. The documented advice is close monitoring. Keep taking ibrutinib as prescribed unless your prescriber tells you otherwise. Tell your pharmacist and prescriber how much kratom you use and how often. Your ibrutinib dose may need to be adjusted and individualized by your care team. Report unusual bleeding or bru… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Ibrutinib and Kratom Interaction
Ask in your own words about taking Ibrutinib and Kratom together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (2)
- Tanna RS, Nguyen JT, Hadi DL, et al: Clinical assessment of the drug interaction potential of the psychotropic natural product kratom. Clin Pharmacol Ther 2023; 113(6):1315-1325. PubMed
- Dhoble LR, Gour A, McCurdy CR, et al: Evaluating the drug interactions in kratom usage: clinical application. Expert Opin Drug Metab Toxicol 2025; 21(8):949-959. DOI
Other Serious Interactions of Ibrutinib and Kratom
Also serious with Kratom
Also serious with Ibrutinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Ibrutinib
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- PiracetamMajor
- Vitamin EModerate
- SeleniumModerate
- GingerModerate
- TurmericModerate
- + 281 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring.
- Moderate Can be significant — usually manageable with monitoring. This interaction.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.